Melatonin review reports cognitive-score gains, with key details missing
Pooled trial results favored melatonin in adults with cognitive impairment, but the abstract leaves the size and practical meaning unclear.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review found higher cognitive-function scores with melatonin in adults who already had cognitive impairment. However, the abstract does not identify the scoring scale or the comparison treatments, making the clinical meaning hard to judge. Its subgroup findings do not establish an optimal administration time or treatment length, and they do not justify general use.
The abstract omits the cognitive scale, confidence intervals and detailed safety results. It therefore cannot establish a clinically meaningful gain or adequately support its broad safety claim.
What was evaluated
The review addressed cognitive function, despite discussing sleep in its background. Its reported outcome was a pooled cognitive-score difference; the abstract does not present a corresponding improvement in everyday functioning.
Reading the subgroups
Statistically significant findings within selected duration, timing and impairment subgroups do not prove those options outperform others. Such claims require direct comparisons, which are not described in this abstract.
The original publication
Effect of melatonin on cognitive function in adults with cognitive impairment: a multi-dimensional meta-analysis of randomized trials.
Leung LY, Tam HL, Asiamah N et al.
Alzheimers Res Ther · 2025
- PubMed ID
- 41185054
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.